Editorial
Published on 15 Aug 2025
Editorial: Current status and recent advances in preclinical models for rare cancers
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1676020
- 322 views
Type at least 3 characters
1,972 articles
Original Research
Published on 15 Aug 2025
Broad-spectrum antitumor analysis of the telomerase activity inhibitor TPCH derived from the human constitutively expressed protein LPTS/PinX1
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1643155
- 266 views
Original Research
Accepted on 14 Aug 2025
NK Cell-Related Genes-Driven Novel Molecular Subtyping and Prognostic Signatures for Wilms Tumor: Uncovering the Therapeutic Potential of TGX-221 and Biomarker Role of HS2ST1
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1593011
- 125 views
Case Report
Accepted on 14 Aug 2025
PEComa Progressed by mTOR Inhibitor Therapy with Anti-VEGFR TKI Combined with PD-1 Inhibitor：a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1628650
- 102 views
Original Research
Accepted on 14 Aug 2025
Evaluation of anti-liver cancer activity and anticancer mechanism of one novel small molecule compound (THY-10A62) targeting FAK pathway
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1498005
Case Report
Accepted on 13 Aug 2025
Chronification of metastatic leiomyosarcoma in 9 lines of therapy by precision oncology: A case report and review of the literature
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1626478
Original Research
Accepted on 13 Aug 2025
Dynamic Alterations in m⁶A RNA Methylation Profiles during Involution of Infantile Hemangiomas
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1652621
Review
Published on 13 Aug 2025
Unraveling the potential: mRNA therapeutics in oncology
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1643444
- 693 views
Original Research
Accepted on 11 Aug 2025
MEX3A is a diagnostic, independent prognostic biomarker and a promising therapeutic target in glioblastoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1585592
- 122 views
Original Research
Accepted on 11 Aug 2025
Outstanding Treatment Success of Pembrolizumab and Bevacizumab Combination Therapy in First-line Treatment of Cervical Sarcomatoid Carcinoma: A Rare Case Report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1586531
- 157 views
Review
Published on 11 Aug 2025
KLF9 in cancer: a potential prognostic marker and therapeutic target
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1630547
- 349 views
Original Research
Published on 11 Aug 2025
Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1544967
- 1,145 views
Systematic Review
Published on 08 Aug 2025
Immune checkpoint inhibitors in pancreatic adenocarcinoma: a systematic review and meta analysis of clinical outcomes
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1569884
- 449 views
Case Report
Published on 08 Aug 2025
Case Report: A rare case of MET-amplified gastric cancer with systemic metastasis: remarkable efficacy of crizotinib and the role of precision medicine
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1555801
- 637 views
Review
Published on 08 Aug 2025
Approaches to modeling cancer metastasis: from bench to bedside
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1602489
- 378 views
Case Report
Published on 07 Aug 2025
Case Report: A rare case of ALK-KIF5B gene fusion benefited from treatment with lorlatinib
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1594072
- 498 views